|
|
|
|
|
Vinorelbine
drug data and news
Vinorelbine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Vinorelbine | ||
| Brand Names/Synonyms | KW 2307; Kw 2307 Base; Navelbine; Navelbine Base; VINORELBINE; Vinorelbin; Vinorelbina [Spanish]; Vinorelbine Bitartrate; Vinorelbine Ditartarate; Vinorelbine Ditartrate; Vinorelbine Tartrate; Vinorelbinum [Latin] | ||
| Indication | For the treatment of non-small-cell lung carcinoma | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Vinorelbine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vinorelbine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. | ||
| Mechanism Of Action | The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. | ||
| Vinorelbine News (When available) |
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug ... May 8, 2006 ADVENTRX Announces 2006 First Quarter Financial Results May 10, 2006 Findings from Greece, the United Kingdom and Tokyo in breast ... May 3, 2006 ADVENTRX ANNOUNCES CLOSING OF MERGER WITH SD PHARMACEUTICALS May 1, 2006 Inex Pharmaceuticals Closes Hana Biosciences Licensing Agreement May 8, 2006 Novacea Announces Initial Public Offering May 10, 2006 Hana acquires anticancer compounds from Inex May 8, 2006 Hana Biosciences Reports First Quarter 2006 Results May 4, 2006 Sequential Two-Drug Combinations Explored in Advanced NSCLC Apr 20, 2006 Herceptin® May Change the Natural History of Patients with HER2 ... May 1, 2006 Additional Evidence that Herceptin® Benefits Women with HER2 ... Apr 17, 2006 | ||
| Dosage Forms | SOLUTION | ||
| Drug_Category | Radiation-Sensitizing Agents; Antineoplastic Agents; ATC:L01CA04 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Vinorelbine: Acute pulmonary reactions have been reported with NAVELBINE and other anticancer vinca alkaloids used in conjunction with mitomycin. Although the pharmacokinetics of vinorelbine are not influenced by the concurrent administration of cisplatin, the incidence of granulocytopenia with NAVELBINE used in combination with cisplatin is significantly higher than with single-agent NAVELBINE. Patients who receive NAVELBINE and paclitaxel, either concomitantly or sequentially, should be monitored for signs and symptoms of neuropathy. Administration of NAVELBINE to patients with prior or concomitant radiation therapy may result in radiosensitizing effects. Caution should be exercised in patients concurrently taking drugs known to inhibit drug metabolism by hepatic cytochrome P450 isoenzymes in the CYP3A subfamily, or in patients with hepatic dysfunction. Concurrent administration of vinorelbine tartrate with an inhibitor of this metabolic pathway may cause an earlier onset and/or an increased severity of side effects. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C45H54N4O8 | ||
| Molecular Weight | 778.932 g/mol | ||
| Smiles String | CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 5.829 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 27.7-43.6 hours | ||
| Protein Binding [%] | ~27% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Vinorelbine.html http://www.rxlist.com/cgi/generic2/vinor.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00101 | ||
| CAS Registry Number | 71486-22-1 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:668899 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2257777 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |